TAI'AN, China, April 27 /PRNewswire-Asia-FirstCall/ -- China Biologic Products, Inc. (Nasdaq:CBPO - News) ("China Biologic," or the "Company"), a leading plasma-based biopharmaceutical company in China, today announced that its majority-owned subsidiary, Shandong Taibang Biological Products Co. Ltd. ("Shandong Taibang"), has been earmarked by the Shandong provincial government, as one of twelve model Shandong-based biopharmaceutical companies, eligible to receive financial subsidies and tax concessions related to new drug research and development in connection with the provincial government's recently announced program to drive growth in the region's biopharmaceutical industry.
